Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ablynx
ClinicalTrials.gov Identifier:
NCT01284569
First received: January 21, 2011
Last updated: February 26, 2013
Last verified: December 2012

January 21, 2011
February 26, 2013
March 2011
October 2012   (final data collection date for primary outcome measure)
Safety: number of treatment emergent adverse events (TEAEs) [ Time Frame: From first study drug administration until last follow-up visit (i.e. 90 days after dosing for single dose part, 210 days after first dose for multiple dose part) ] [ Designated as safety issue: Yes ]
Safety: number of treatment emergent adverse events (TEAEs) [ Time Frame: From first study drug administration until last follow-up visit (i.e. 90 days after dosing for single dose part, 120 days after first dose for multiple dose part) ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01284569 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics (PK): serum concentration of ALX-0061 [ Time Frame: From first day prior to study drug administration until last follow-up visit (i.e. 90 days after dosing for single dose part, 210 days after first dose for multiple dose part) ] [ Designated as safety issue: No ]
  • Biological efficacy: pharmacodynamic (PD) markers [ Time Frame: From first day prior to study drug administration until last follow-up visit (i.e. 90 days after dosing for single dose part, 210 days after first dose for multiple dose part) ] [ Designated as safety issue: No ]
    C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum amyloid A (SAA), fibrinogen, interleukin 6 (IL6), soluble IL6 receptor (sIL6R), tumour necrosis factor alpha (TNFalpha), interleukin 1 beta (IL1beta), interferon gamma (IFNgamma)
  • Disease activity: RA-related assessments [ Time Frame: From first day prior to study drug administration until last follow-up visit (i.e. 90 days after dosing for single dose part, 210 days after first dose for multiple dose part) ] [ Designated as safety issue: No ]
    ACR response, DAS28 score, EULAR response
  • Pharmacokinetics (PK): serum concentration of ALX-0061 [ Time Frame: From first day prior to study drug administration until last follow-up visit (i.e. 90 days after dosing for single dose part, 120 days after first dose for multiple dose part) ] [ Designated as safety issue: No ]
  • Biological efficacy: pharmacodynamic (PD) markers [ Time Frame: From first day prior to study drug administration until last follow-up visit (i.e. 90 days after dosing for single dose part, 120 days after first dose for multiple dose part) ] [ Designated as safety issue: No ]
    C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum amyloid A (SAA), fibrinogen, interleukin 6 (IL6), soluble IL6 receptor (sIL6R), tumour necrosis factor alpha (TNFalpha), interleukin 1 beta (IL1beta), interferon gamma (IFNgamma)
  • Disease activity: RA-related assessments [ Time Frame: From first day prior to study drug administration until last follow-up visit (i.e. 90 days after dosing for single dose part, 120 days after first dose for multiple dose part) ] [ Designated as safety issue: No ]
    ACR response, DAS28 score, EULAR response
Not Provided
Not Provided
 
Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients
A Phase I/II, Randomised, Double-Blind, Placebo Controlled Study, Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Single and Multiple Intravenous Doses of ALX-0061 in Patients With RA

The purpose of this study is to determine whether the ALX-0061, a Nanobody targeting the receptor for interleukin 6 (IL6R), is safe and effective after single or multiple administrations to patients with rheumatoid arthritis (RA). Patients will receive different single or multiple doses of either placebo or ALX-0061.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Rheumatoid Arthritis
  • Biological: ALX-0061
    Intravenous administration, single dose (0.3-1-3-6-8 mg/kg) or multiple dose (Biologically effective dose, once every 4 weeks or once every 8 weeks, for 24 weeks)
  • Biological: Placebo
    Intravenous administration, single dose or multiple dose (once every 4 weeks or once every 8 weeks, for 12(/24) weeks; switch to ALX-0061 in weeks 13-24 if no response after first 12 weeks)
  • Experimental: ALX-0061
    Intervention: Biological: ALX-0061
  • Placebo Comparator: Placebo
    Intervention: Biological: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
65
Not Provided
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Body mass index (BMI) <35.0 kg/m2
  • Diagnosed with rheumatoid arthritis (RA) according to the 2010 European League Against Rheumatism (EULAR)/ American College of Rheumatology (ACR) criteria for at least 6 months prior to randomisation
  • Treatment with methotrexate (MTX) for at least 12 weeks prior to screening, with at least 4 weeks before screening at a stable dose, that will remain stable throughout the study period. Inadequate response or or intolerance to disease modifying antirheumatic drugs (DMARDs) (including MTX, where a patient may remain on treatment with %TX at a lower dose for improved tolerance, but with reduced effectiveness)
  • For patients (men and women) of reproductive potential, use of an acceptable method of contraception for the duration of the study. Female patients must be willing to use appropriate birth control measures that would prevent pregnancy starting from the time of signing the informed consent until 90 days after the last dose of study drug is administered
  • For single dose part: Disease Activity Score using 28 joint counts (DAS28) score >= 2.4
  • For multiple dose part: DAS28 score >= 3.2
  • For multiple dose part: swollen joint count >= 3

Exclusion Criteria:

  • A documented history of an autoimmune disease other than RA (other than secondary Sjögren's syndrome)
  • Functional class IV by ACR classification
  • Any new/additional biologic DMARD therapy, cytotoxic drugs and immunosuppressants within four weeks prior to screening, and between screening and Day 1 with the exception of ALX-0061
  • Suspicion of active tuberculosis verified by quantiferon test and abnormal chest X-ray
  • Female patients who are pregnant during the study, or are breastfeeding
  • History of anaphylactic reactions to protein therapeutics
  • Participation in an investigational drug study within 60 days prior to drug administration except for the patients who participated in the single dose part of this study and who are eligible to participate in the multiple dose part
  • Donation of more than 300 mL of blood within 60 days prior to drug administration
  • Malignancy, or prior malignancy, with a disease free interval of <5 years after diagnosis and intervention except curative treatment for non-melanoma skin cancer or resected carcinoma in situ
  • Any current or recent (within 4 weeks prior to first dose) signs or symptoms of infection that requires parenteral antibiotic administration, any known active viral infection (hepatitis B virus [HBV], hepatitis C virus [HCV], human immunodeficiency virus [HIV]) that would impair the participation in the study
  • Major surgery (including joint surgery) within 8 weeks prior to screening and hospitalisation for a clinically relevant event within the 4 weeks prior to screening
  • Any other disease, metabolic dysfunction, physical examination finding, or clinically significant laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk for treatment complications
  • Administration of a live, attenuated vaccine within 1 month before dosing with ALX-0061, or anticipation that such a live attenuated vaccine will be required during the study or within 60 days after the last dose
  • For multiple dose part: contraindication to MRIs or the use of contrast agents for MRI scanning
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Czech Republic,   Hungary,   Poland
 
NCT01284569
ALX-0061-1.1/10
Yes
Ablynx
Ablynx
Not Provided
Study Director: Josefin-Beate Holz, MD Ablynx NV
Ablynx
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP